GENSCRIPT BIO (01548.HK): Legend to Present CARVYKTI Data at ASH 2026

NewTimeSpace News: On 5 November 2026, Genscript Biotech Corporation (stock code: 01548) announced that its associate Legend Biotech Corporation filed a Form 6-K with the US Securities and Exchange Commission on 4 November 2026 (New York time), announcing that Legend will deliver two oral presentations, two poster presentations and one ePublication on CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 68th American Society of Hematology (ASH) Annual Meeting.

The ASH Annual Meeting will take place from 12 to 15 December 2026 in New Orleans, Louisiana. In addition to the CARVYKTI data, Legend will present a poster on LUCAR-G39D, an anti-CD20/CD19 dual-CAR allogeneic gamma delta T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, and a poster on LB2501, its first-in-human in vivo CD19/CD20 dual-targeting CAR-T therapy being evaluated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Legend is an associate of Genscript and its shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market. The announcement also carries cautionary notes on forward-looking statements, noting the uncertainties inherent in drug development and that actual results may differ materially from expectations.